Hepatitis Drug

Dynavax Technologies stock fell from $11.60 to $4.10 this month after its hepatitis drug Heplisav-B was found to be dangerous, shareholders claim in two federal class actions.

SAN FRANCISCO – Dynavax Technologies stock fell from $11.60 to $4.10 this month after its hepatitis drug Heplisav-B was found to be dangerous, shareholders claim in two federal class actions.

Categories / Business, Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.